The brains of people under anesthesia respond to stimuli as they do in the deepest part of sleep - lending credence to a developing theory of consciousness and suggesting a new method to assess loss of consciousness in conditions such as coma. Scientists at the University of Wisconsin School of Medicine and Public Health, led by brain researcher Fabio Ferrarelli, reported their findings in this week's edition of the Proceedings of the National Academy of Science. The group gave the anesthetic midazolam, commonly used at lower doses in "conscious sedation" procedures such as colonoscopies, to volunteers. Then they used transcranial magnetic stimulation (TMS), a noninvasive technique to stimulate the brain cortical neurons from the scalp, in combination with electroencephalography (EEG), which recorded the TMS-evoked brain responses.
Wyeth Consumer Healthcare Withdraws Its Marketing Authorisation Application For Ibuprofen Diphenhydramine Hydrochloride Wyeth
The European Medicines Agency has been formally notified by Wyeth Consumer Healthcare of its decision to withdraw its application for a centralised marketing authorisation for the medicine Ibuprofen/Diphenhydramine Hydrochloride Wyeth 200 mg/25 mg soft capsules. This medicine was intended to be used for the short-term treatment of mild to moderate pain in adults who experience sleeplessness as a result of the pain. The application for the marketing authorisation for Ibuprofen/Diphenhydramine Hydrochloride Wyeth was submitted to the Agency on 4 December 2008. At the time of the withdrawal, it was under review by the Agency's Committee for Medicinal Products for Human Use (CHMP).
SRI International, an independent nonprofit research and development institute, has announced that Thomas S. Kilduff, Ph.D., director of SRI International's Center for Neuroscience, has been named a Fellow of the American Association for the Advancement of Science (AAAS). The award, announced in the December 18, 2009 issue of the journal Science, recognizes researchers' efforts toward advancing science applications that are deemed scientifically or socially distinguished. Dr. Kilduff was honored for his contributions in neuroscience, particularly his role in the discovery of the neuropeptide hypocretin, and for his service to the Sleep Research Society.
Obstructive Sleep Apnea (OSA) adversely affects glucose control in patients with type 2 diabetes, according to a study conducted by researchers at the University of Chicago. The study "demonstrates for the first time that there is a clear, graded, inverse relationship between OSA severity and glucose control in patients with type 2 diabetes, " wrote lead author, Renee S. Aronsohn, M.D., instructor of medicine at the University of Chicago. The study also confirmed other reports that undiagnosed OSA is very common among patients with type 2 diabetes, indicating that it is largely unrecognized additional medical risk factor in these patients.
Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today provided an update on the status of its New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia. Somaxon held a meeting with senior leadership at the U.S. Food and Drug Administration (FDA) on January 20, 2010 to discuss the issues raised by the FDA in the Complete Response Letter Somaxon received in December 2009 relating to the Silenor NDA.
Dr. Oz Show Focuses On Patients With Sleep Disorders Spotlight On 20 Million Americans With Sleep Apnea
Watermark Medical CEO Sean Heyniger, said the recent Dr. Oz Show segment on sleep apnea and obesity will help the estimated 20 million undiagnosed Americans realize their symptoms and seek help. Watermark's ARESTM is an innovative, low-cost, patient-friendly wireless device, offered through primary care physicians that is worn while the patient sleeps at home. The device collects physiological data and integrates it with clinical history to determine the presence and severity of obstructive sleep apnea (OSA). John Sculley, Co-Chairman of the Board for Watermark Medical, said, "The Watermark platform helps transform the manner in which healthcare is delivered by lowering costs and focusing on outcomes and therapy compliance.